There will be the opportunity to pick-up AMAG at much lower levels. The current price assumes a 75% or greater chance of approval. I personally believe that the risk is much higher than 25% of a 3rd rejection from the FDA. They are trying to argue for an acute label in a disease that is chronic. Does not make sense, although the management team and the institutional investors are very proactive.